
2.5M
AED · Asking price
Profitable Multi-Speciality Polyclinic & Pharmacy in Dubai
Dubai, United Arab Emirates
- Revenue
- AED 973K
- Profit
- AED 0
- Whole price / annual profit
- —

Exit readiness
7 of 100
Exit readiness. How much of the paperwork buyers ask for in diligence is already in this listing’s data room.
Illustrative image. This photo may be AI-generated and may not show the actual business or its assets.
This ratio uses the whole business asking price and the latest closed financial year’s net profit. It can differ from the seller’s SDE or EBITDA valuation multiple.
Sign up free to contact the seller
A pharmaceutical regulatory and compliance services group providing GxP auditing, EU GMP and OECD GLP certification support, regulatory affairs and life-cycle management (marketing-authorisation holding, pharmacovigilance) and technology transfer services to generic-drug, API and biosimilar developers, manufacturers and marketers. Revenue mixes fixed-price turnkey projects, repeat three-yearly compliance cycles and recurring MA-holding/pharmacovigilance mandates, supplemented by sales from a digital library of several hundred ready-to-use audit reports. The group employs 46 staff across Europe, Asia and MENA, serves 300+ clients in 40+ countries, earns roughly half of revenue from repeat customers, and its largest client represented 6.9% of FY2025 revenue.
The founder is divesting the services business to focus full-time on the affiliated products business, carved out into a separate entity in January 2026, which he will continue to lead. Management, clients and operating structure remain in place, with a handover period agreed.
Single-window GxP compliance, regulatory and technology services for generic pharma, APIs and biosimilars. Five lines: GxP audits (150–200 per year, plus a Digital Audit Library of 500+ ready-to-purchase reports); EU GMP and OECD GLP certification turnkey projects (65+ facilities certified, 20+ ongoing); regulatory affairs and market access (CTD dossiers, MA holding, pharmacovigilance, batch release); technology (product development, tech transfer, bioequivalence, 100+ technologies available); facility design, QMS remediation and sourcing.
300+ clients across 40+ countries, from large pharma to SMEs. Revenue by region in FY2025: China 32%, Europe & CIS 26%, India 23%, rest of Asia 16%, MEA 3%. Low concentration — the largest client is 6.9% of revenue and the top five together 28.8%. Around 50% of 2025 revenue came from repeat customers, with 25–30 key accounts, some served every year since 2006. GMP audits must be renewed every three years, which builds a natural recurring cycle.
46 employees, rising to 55 by 2029. Asset-light model with operations teams based in India (44%) and China (26%), keeping the cost base low, and client-facing offices in Malta, Germany and Dubai. Staff turnover below 12% since inception. Second-line management is fully in place: a COO with 33 years of experience leads all operations, and each head of department brings at least 15 years in their specialism. Business development, operations and management already run largely independently of the Founder, who will stay on for a handover period.
Order book of EUR 9.0+ million in signed contracts, 53% still to be invoiced and revenue visibility through to Q2 2029, plus EUR 2.5+ million in projects under negotiation. 50+ GMP audits are already scheduled for 2026. Three new service lines are in the pipeline: biosimilars consulting (two monoclonal antibodies with patents expiring 2029–30), CRO design and commissioning in greenfield markets, and a dedicated Brazil/ANVISA desk. The carved-out products business remains a captive client under a master service agreement, contributing an estimated EUR 624k in 2026 and rising to EUR 1.5 million by 2029. EBITDA margin is projected at 40%+ from 2027 onwards.
What the seller filed for each closed financial year, plus a trend for next year worked out from those years. The full accounts and the line-by-line detail sit behind an enquiry.
| Financial year | Revenue | EBITDA |
|---|---|---|
| FY2023 | AED 2,337,000 | AED 549,000 |
| FY2024 | AED 2,915,000 | AED 1,218,000 |
| FY2025 | AED 3,867,000 | AED 1,478,000 |
| FY2026Part year, up to November 2026 | AED 4,338,000 | AED 1,682,000 |
| FY2026 (trend) | AED 4,569,667 | AED 2,010,667 |
FY2026 is a part year: it covers only the months up to November 2026. It is not a full year, so it should not be compared with the full years, and it is not used in the trend.
SellAnyBiz works this trend out from the 3 closed financial years above: a straight-line (least-squares) trend through them, extended one year, the same way for every listing. It is not a figure the seller gave.
The seller's own method comes first. The other tabs read the same figures a different way — only methods the seller's figures can actually answer are shown.
EBITDA multiple
AED 13,440,000
EBITDA AED 1.7M × 8.00
The valuation covers the whole business. The asking price includes the seller’s premium or discount. A stake offer uses its proportional share of the asking price.
Similar deals buyers are exploring right now.

2.5M
AED · Asking price
Dubai, United Arab Emirates

7.9M
EUR · Asking price
Savona, Italy

50.4M
AED · Asking price
Abu Dhabi, United Arab Emirates

2.1M
AED · Asking price
Abu Dhabi, United Arab Emirates

7M
AED · Asking price
Dubai, United Arab Emirates

1.8M
AED · Asking price
United Arab Emirates

2.5M
AED · Asking price
Dubai, United Arab Emirates

2M
AED · Asking price
Dubai, United Arab Emirates
Asking price
AED 13.4M
Sign up free to contact the seller